
Shield Therapeutics takes full US control of ACCRUFeR, boosting growth prospects with no upfront cost.
Shield Therapeutics has agreed to take full commercial control of its oral iron therapy ACCRUFeR in the US from Viatris starting September 30, without any upfront payment. Instead, Shield will pay reduced royalties on US sales over five years. This m...


